PILL stock forecast, quote, news & analysis

Key Takeaways

• PILL is a 3x leveraged ETF that seeks 300% of the daily return of the S&P Pharmaceuticals Select Industry Index, magnifying both gains and losses.
• Over the last 30 days, PILL has climbed roughly 22%, rebounding from a mid-October low near $13.40 to about $16.77.
• The rally was driven by a broad pharmaceutical and biotech recovery during third-quarter earnings season and a post-election, risk-on shift in sentiment.
• The longer quarterly trend remains negative, with the fund still down roughly 17% from mid-August levels despite the recent bounce.
• Because PILL rebalances daily, its returns compound and can diverge significantly from three times the index over periods longer than a single day.
• Investors can explore detailed Price Targets, Earnings, and Forecast pages for additional analysis of this ticker.
• For automated, data-driven trading ideas across the market, explore Trending AI Robots.

Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) Company Overview and Market Position

PILL is the Direxion Daily Pharmaceutical & Medical Bull 3X Shares, a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Pharmaceuticals Select Industry Index. The fund was launched in November 2017 and is listed on NYSE Arca, with a net expense ratio of approximately 0.97%. It is managed by Rafferty Asset Management and uses swaps, futures, and other derivatives to achieve its leveraged exposure.

The underlying index is a modified equal-weighted benchmark composed of pharmaceutical and medical stocks within the S&P Total Market Index, classified under the GICS pharmaceuticals sub-industry. Because the index is equal-weighted rather than market-cap weighted, mid- and small-cap pharmaceutical names carry proportionally more influence than in traditional large-cap health care funds. Investors follow PILL primarily as a short-term tactical tool to express a leveraged view on the pharmaceutical sector, understanding that the fund is non-diversified and designed for daily, rather than long-term, holding periods.

Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, PILL has delivered a strong rebound, rising from a closing level of $13.70 on October 13 to approximately $16.77, a gain of roughly 22%. The move reflects a sharp recovery off the fund's recent trough: PILL bottomed near $13.41 in mid-October before advancing through late October and early November, reaching the upper $17 range.

The broader quarterly picture tells a more mixed story. About three months ago, PILL was trading near $20, having peaked above $23 in mid-August. From those levels, the fund declined steadily through September and early October before the current rebound. As a result, PILL remains down roughly 17% from its mid-August levels despite the 30-day advance. This volatility is characteristic of a 3x leveraged product, which amplifies the underlying index's daily movements in both directions.

What Drove PILL Stock Price in the Last 30 Days

The recent 22% advance has been powered by a broad recovery in pharmaceutical and biotech equities, magnified by PILL's 3x daily leverage. Third-quarter earnings season provided much of the fundamental support. Major drug makers delivered results and guidance that lifted sector sentiment, including Gilead Sciences (GILD), which raised its full-year product sales outlook, and Vertex Pharmaceuticals (VRTX), which increased its 2026 revenue guidance after closing an acquisition. Amgen (AMGN) reported double-digit sales growth across much of its portfolio, while Moderna (MRNA) raised its 2026 growth outlook and received a price-target increase. Eli Lilly (LLY) also gained on positive clinical data.

Sentiment was further supported by a post-election risk-on rally in early November, in which pharmaceutical and biotech names joined a broad market advance. Because the S&P Pharmaceuticals Select Industry Index is equal-weighted, the strength in mid- and small-cap pharma names had an outsized effect, and PILL's leverage amplified those gains. The move also represents a recovery from oversold conditions created by the September-to-October drawdown.

What Drove PILL Stock Performance Over the Last Quarter

Over the past three months, PILL's trajectory has been defined by a steep decline followed by a partial recovery. After peaking above $23 in mid-August, the fund slid through September and early October, weighed down by a rotation away from health care and defensive sectors amid shifting interest-rate expectations and broader market uncertainty. Within the sector, a handful of high-profile disappointments contributed to the weaker tone, including guidance cuts and post-earnings selloffs at certain biopharmaceutical names.

The rebound that began in late October was driven by improving earnings results, guidance raises from major pharmaceutical companies, and a return of risk appetite. Because PILL seeks 3x daily exposure and rebalances each day, the compounding effect of these swings can produce returns over weeks and months that differ meaningfully from a simple three-times multiple of the index's cumulative move. This structural feature is central to understanding the fund's sharp quarter-over-quarter volatility.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's automated trading systems. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers across the market, but only the top-performing and most relevant bots are featured in this section. The robots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon swing and trend-following systems. Each bot's track record and methodology are presented so users can evaluate them alongside their own objectives. For investors seeking a data-driven, systematic complement to manual analysis, the page provides a useful starting point for exploring automated strategies.

PILL Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape PILL's direction. Ongoing quarterly earnings reports and guidance updates from major pharmaceutical companies will remain key catalysts, along with upcoming FDA decision dates and clinical trial readouts that can move individual index constituents. Macroeconomic conditions, including inflation data and the path of interest rates, will continue to influence sector rotation into and out of health care. Policy and regulatory developments, such as drug-pricing measures, also carry the potential to shift pharmaceutical sentiment broadly.

For a leveraged fund like PILL, investors should additionally account for the structural risks inherent in daily 3x exposure, including volatility decay and the compounding of daily returns, which make the fund unsuitable as a passive long-term holding. These dynamics mean that monitoring the underlying index's daily movements is essential, rather than relying on expectations of simple three-times performance over multi-week periods.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations